Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Explore this paper's citation graph
Summary
Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.
- Type
- article
- Published
- 2011-03-23
- Cited by
- 3,415
- References
- 70
- Access
- Open access
- OpenAlex
- https://openalex.org/W1980497534
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4970282
Keywords
T790M, Epidermal growth factor receptor, Cancer research, Lung cancer, EGFR inhibitors
References
- Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
- Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
- Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
- Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC
- Differential retinoblastoma and p16INK4A protein expression in neuroendocrine tumors of the lung
- Modeling oncogene addiction using RNA interference
- EGFR mutations in small-cell lung cancers in patients who have never smoked.
- Expression of p16 and lack of pRB in primary small cell lung cancer
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
- The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.
- Pharmacokinetics in melanoma-bearing mice of 5-dihydroxyboryl-6-propyl-2-thiouracil (BPTU), a candidate compound for boron neutron capture therapy.
- Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Cited by
- Klinische Studien in der Ära der molekular stratifizierten Therapie
- Das fortgeschrittene Lungenkarzinom
- Guidance for life, cell death, and colorectal neoplasia by netrin dependence receptors.
- The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.
- SnapShot: non-small cell lung cancer.
- Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
- Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF.
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers
- Unintentional Weakness of Cancers: The MEK–ERK Pathway as a Double-Edged Sword
- Personalizing Therapy in Advanced Non–Small Cell Lung Cancer
- Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.
- Recent evidence, advances, and current practices in surgical treatment of lung cancer.
- Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
- Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
- Management of EGFR mutated nonsmall cell lung carcinoma patients
- The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
- Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models
- EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
- Cell-free DNA as a novel marker in cancer therapy.
- Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
Related papers
- EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib.
- Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
- Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model
- Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
- Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
- Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
- Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
- Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors
- The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor